Literature DB >> 7413057

Development of 'primary' hyperparathyroidism during lithium therapy: longitudinal study.

C Christiansen, P C Baastrup, I Transbøl.   

Abstract

The bone mineral content and the serum levels of immunoreactive parathyroid hormone (iPTH), and protein-corrected calcium and magnesium were measured in 13 manic depressive patients before and during treatment with lithium. Initially all four parameters were normal. During the treatment the bone mineral decreased and the serum levels of iPTH, calcium, and magnesium increased. Although altered metabolism of parathyroid hormone cannot be ruled out, these data, together with other observations, suggest that a mild 'primary' hyperparathyroidism sets in quite early after institution of lithium therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7413057     DOI: 10.1159/000117770

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  5 in total

Review 1.  Emerging therapeutic opportunities for skeletal restoration.

Authors:  Masanobu Kawai; Ulrike I Mödder; Sundeep Khosla; Clifford J Rosen
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

2.  Effect of lithium maintenance therapy on thyroid and parathyroid function.

Authors:  M Kusalic; F Engelsmann
Journal:  J Psychiatry Neurosci       Date:  1999-05       Impact factor: 6.186

Review 3.  Lithium intoxication: a coordinated treatment approach.

Authors:  S L Minden; E L Bassuk; S P Nadler
Journal:  J Gen Intern Med       Date:  1993-01       Impact factor: 5.128

Review 4.  Lithium therapy and hyperparathyroidism: an evidence-based assessment.

Authors:  Brian D Saunders; Erika F H Saunders; Paul G Gauger
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

5.  Effects of maintenance lithium treatment on serum parathyroid hormone and calcium levels: a retrospective longitudinal naturalistic study.

Authors:  Umberto Albert; David De Cori; Andrea Aguglia; Francesca Barbaro; Fabio Lanfranco; Filippo Bogetto; Giuseppe Maina
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-20       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.